证券之星消息，8月19日中药板块较上一交易日上涨0.57%，ST香雪领涨。当日上证指数报收于3727.29， 下跌0.02%。深证成指报收于11821.63，下跌0.12%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300147 | ST香雪 | 10.54 | 20.05% | 66.89万 | | 6.52亿 | | 600594 | 益僧制药 | 4.59 | 10.07% | 42.52万 | | 1.89亿 | | 603139 | 康惠制药 | 25.18 | 10.00% | 3.83万 | | 9369.95万 | | 002873 | 新天药业 | 15.19 | 9.99% | 1 29.29万 | | 4.38亿 | | 600557 | 康家药业 | 19.83 | 9.98% | 39.16万 | | 7.74亿 | | 600671 | 天目药业 | 16.89 | 6.03% | 9.59万 | | 1.58亿 | | ...

新天药业盘中涨停，已连收3个涨停板，截至9:43，该股报15.19元，换手率10.71%，成交量2556.67万 股，成交金额3.81亿元，涨停板封单金额为2.74亿元。连续涨停期间，该股累计上涨33.13%，累计换手 率为50.37%。最新A股总市值达37.08亿元，A股流通市值36.25亿元。 龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%上榜龙虎榜1次，买卖居前营业部 中，机构净卖出895.28万元，营业部席位合计净买入2050.92万元。 7月31日公司发布的半年报数据显示，上半年公司共实现营业总收入3.58亿元，同比下降18.89%，实现 净利润576.61万元，同比下降81.00%。（数据宝） 近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.08.18 | 10.04 | 21.73 | 12756.46 | | 2025.08.15 | 9.99 | 17.92 | 9895.06 | | 2025.08.14 | 1.15 | 14.31 | 1637.00 | | ...

Group 1 - The A-share market saw a significant rise in pharmaceutical stocks, with notable performances including Furuide Co., Ltd. hitting a 20% limit up, and Boji Pharmaceutical rising by 14% [1] - Other companies such as Jimin Health and Kangyuan Pharmaceutical also experienced substantial gains, with both reaching a 10% limit up [1] - The overall trend indicates a bullish sentiment in the pharmaceutical sector, with multiple stocks showing increases of over 5% [1] Group 2 - Furuide Co., Ltd. reported a market capitalization of 19.1 billion and a year-to-date increase of 129.01% [2] - Boji Pharmaceutical had a market cap of 4.819 billion and a year-to-date increase of 43.33% [2] - Other notable companies include Jimin Health with a market cap of 5.66 billion and a year-to-date increase of 58.76%, and Kangyuan Pharmaceutical with a market cap of 11.2 billion and a year-to-date increase of 45.59% [2]

Market Overview - The A-share market continued to rebound, with the Shanghai Composite Index rising by 0.44%, the Shenzhen Component Index by 0.57%, and the ChiNext Index by 1.04% as of 9:45 AM on August 19 [1] - The pharmaceutical sector showed strong performance, particularly in innovative drugs, with Ji Min Health hitting the daily limit [1] - AI hardware stocks like New Yisheng and Zhongji Xuchuang reached historical highs, while sectors such as film, media, military, banking, oil and gas, and wind power experienced declines [1] Key Sectors Innovative Drug Sector - The innovative drug sector saw significant gains, with Ji Min Health and Kangyuan Pharmaceutical hitting the daily limit, and other companies like Nuo Si Lan De and Li Fang Pharmaceutical also rising [2] - CITIC Securities reports a favorable policy environment for innovative drugs starting from 2025, recommending investments in innovation-driven and internationalization strategies, particularly in the innovative drug field [2] CPO Concept - CPO concept stocks maintained strong performance, with New Yisheng and Zhongji Xuchuang reaching historical highs, and companies like Jianqiao Technology and Tengjing Technology also seeing gains [3] - CITIC Jiantou Securities highlights a shift in AI training network architecture, leading to increased demand for optical modules, with 800G optical modules expected to see significant growth starting in 2023 [3] Institutional Insights Shenwan Hongyuan - Shenwan Hongyuan believes the short-term bull market atmosphere will continue to dominate, with a focus on securities, insurance, military, and rare earth sectors before early September [4] - The firm emphasizes the importance of sectors with scarce overseas computing power and suggests a price alliance in high market share manufacturing segments [4] Huatai Securities - Huatai Securities suggests that the market may have entered the mid-stage of a bull market, characterized by structural features and rapid sector rotation [5] - The firm notes that the current slow bull market may extend the upward cycle, with a need for increased market signals to attract more external funds [5] Dongfang Securities - Dongfang Securities anticipates no major adjustment risks for stock indices in August, with a "local advance, multi-point bloom" characteristic in the current market [6] - The firm advises caution against potential pullbacks and emphasizes the importance of "high-low switching" in the event of market adjustments, recommending focus on technology autonomy, innovative drugs, military, and robotics sectors [6]

Group 1 - The company clarified that recent rumors regarding its entry into the supply chains of Nvidia, Meta, Google, Huawei, and Cambricon are false, stating that no contracts have been signed with these companies [2][5][6] - Since August 11, the company's stock has experienced significant volatility, with five out of six trading days hitting the daily limit, resulting in an approximate 70% increase in stock price, reaching a multi-year high [2][6] - The company operates in two main business segments: energy and set-top boxes, with key products including 18650 lithium batteries, various polymer soft-pack batteries, digital TV set-top boxes, smart terminals, and comprehensive digital TV solutions [4] Group 2 - The company's half-year report indicated substantial growth in revenue and profit for the first half of 2025, driven by the ongoing production and sales of high-power power supply products [6] - Other companies, such as Yingweike and Huasheng Tiancai, have also issued announcements to clarify market rumors, with Yingweike's stock rising over 110% since the end of July [7][12] - Huasheng Tiancai's stock has seen a cumulative increase of 106.8% since July 18, 2025, although the company noted that its stock price has diverged significantly from its fundamental performance [14]

格隆汇8月18日丨新天药业(002873.SZ)公布股票交易异常波动暨风险提示公告，经自查，公司正在筹划 拟使用自有资金不超过4,000万元，通过"增资+受让"方式，对参股公司汇伦医药追加股权投资事项，本 次拟"增资+受让"方式投资汇伦事项完成后，预计公司持有汇伦医药的股权比例将由14.5971%增加至 15.4567%，汇伦医药仍为公司的参股公司。该事项待召开董事会议审议，尚存在不确定性。董事会议 审议后，公司将及时履行信息披露义务。 登录新浪财经APP 搜索【信披】查看更多考评等级 ...

一、复牌 1、中国船舶：已刊登异议股东收购请求权申报结果，股票复牌。 二、并购、定增 1、爱柯迪：拟发行股份及支付现金购买卓尔博71%股权。 2、引力传媒：拟定增募资不超过4.7亿元，用于全球社交营销云项目、内容创意云项目、补充流动资 金。 三、回购 1、山东玻纤：将股份回购价格上限由5.41元/股调整为10.22元/股。 2、二连板新天药业：正在筹划对参股公司汇伦医药追加股权投资。 3、特变电工：拟发行可转债募资不超过80亿元，用于准东20亿Nm3/年煤制天然气项目。 4、久吾高科：拟发行可转债募资不超过5.04亿元，用于班戈错盐湖年产2000吨氯化锂中试生产线BOT 项目、特种无机膜组件及装置生产线项目、补充流动资金。 5、蔚蓝锂芯：控股子公司淮安光电在马来西亚进行LED项目建设投资，项目总投资8388万美元，新建 LED CSP项目；项目全部建成达产后，预计将形成700KK芯片点测分选及CSP芯片封装月产能。 2、海正生材：拟将回购股份价格上限由12元/股（含）调整为17元/股（含），并同时对回购实施期限 延长6个月，延长至2026年2月27日止。 四、对外投资 1、景嘉微：拟2.2亿元增资诚恒微成为其 ...

每经AI快讯，8月18日，新天药业(002873.SZ)公告称，公司股票连续三个交易日收盘价格涨幅偏离值累 计超过20%，属于股票交易异常波动情况。经核实，公司生产经营一切正常，未发现存在对公司股票交 易价格可能产生重大影响的媒体报道、市场传闻等。公司正在筹划拟使用自有资金不超过4,000万元， 通过"增资+受让"方式，对参股公司汇伦医药追加股权投资事项，完成后预计持有汇伦医药的股权比例 将增加至15.4567%，汇伦医药仍为公司的参股公司。该事项待召开董事会议审议，尚存在不确定性。 ...

证券代码：002873 证券简称：新天药业 公告编号：2025-049 贵阳新天药业股份有限公司 股票交易异常波动暨风险提示公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、贵阳新天药业股份有限公司（以下简称"公司"或"本公司"）股票于 2025 年 8 月 14 日、2025 年 8 月 15 日、2025 年 8 月 18 日连续三个交易日内收 盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规则》的相关规定， 属于股票交易异常波动的情况。 2、经公司自查并向控股股东、实际控制人等相关方核实，公司生产经营一 切正常，未发现存在对公司股票交易价格可能产生重大影响的媒体报道、市场传 闻等。公司正在筹划拟通过"增资+受让"方式，对参股公司上海汇伦医药股份 有限公司（以下简称"汇伦医药"）追加股权投资事项，本次拟"增资+受让" 方式投资汇伦事项完成后，汇伦医药仍为公司的参股公司。该事项待召开董事会 议审议，尚存在不确定性。除此之外，公司不存在其他应披露而未披露的重大事 项。 3、敬请广大投资者注意二级市场交易风险，理性决策，审慎投 ...

沪指8月18日上涨0.85%，申万所属行业中，今日上涨的有29个，涨幅居前的行业为通信、综合，涨幅 分别为4.46%、3.43%。医药生物行业今日上涨1.07%。跌幅居前的行业为房地产、石油石化，跌幅分别 为0.46%、0.10%。 资金面上看，两市主力资金全天净流出160.57亿元，今日有8个行业主力资金净流入，电子行业主力资 金净流入规模居首，该行业今日上涨2.48%，全天净流入资金50.40亿元，其次是通信行业，日涨幅为 4.46%，净流入资金为49.04亿元。 主力资金净流出的行业有23个，非银金融行业主力资金净流出规模居首，全天净流出资金70.87亿元， 其次是电力设备行业，净流出资金为50.90亿元，净流出资金较多的还有医药生物、基础化工、房地产 等行业。 医药生物行业今日上涨1.07%，全天主力资金净流出47.06亿元，该行业所属的个股共474只，今日上涨 的有347只，涨停的有7只;下跌的有119只。以资金流向数据进行统计，该行业资金净流入的个股有155 只，其中，净流入资金超亿元的有7只，净流入资金居首的是塞力医疗，今日净流入资金1.52亿元，紧 随其后的是福瑞股份、新天药业，净流入资金分别 ...